A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR-M61S and LCAR-M61D Cell Preparations in Patients With Relapsed/Refractory Multiple Myeloma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Enrollment
- 66
- Locations
- 4
- Primary Endpoint
- Dose-limiting toxicity (DLT) rate
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
A prospective, two-cohort, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61S and LCAR-M61D in patients with relapsed/refractory multiple myeloma.
Detailed Description
This study was a prospective, two-cohort, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61S and LCAR-M61D in patients with relapsed/refractory multiple myeloma. All subjects who meet the eligibility criteria will receive intravenous injection of LCAR-M61S or LCAR-M61D cell injection. The study will include the following sequential phases: screening, apheresis, pre-treatment (lymphodepleting chemotherapy), treatment, and follow-up.
Investigators
Chen Lijuan
Professor
The First Affiliated Hospital with Nanjing Medical University
Eligibility Criteria
Inclusion Criteria
- •Subjects voluntarily participate in clinical research;
- •Age ≥18 years old;
- •Eastern Cooperative Oncology Group (ECOG) score 0-2;
- •Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria;
- •Measurable lesions were present;
- •Subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (PD confirmed according to IMWG criteria);
- •Expected survival ≥3 months;
- •Clinical laboratory values in the screening period meet criteria;
Exclusion Criteria
- •Received previous therapy targeting GPRC5D and/or CD19 targets;
- •Prior antineoplastic therapy and meet exclusion criteria (before apheresis);
- •Subjects had Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.
- •Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;
- •Life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CAR-T cell formulations or their excipients, including DMSO, are known.
- •Serious underlying diseases were present;
- •Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment.
- •Also enrolled in other clinical studies.
Outcomes
Primary Outcomes
Dose-limiting toxicity (DLT) rate
Time Frame: From LCAR-M61S and LCAR-M61D cell preparations infusion (Day 1) until the 30th day of follow-up period, assessed up to 30 days
DLT was classified according to the NCI-CTCAE V5.0 toxicity evaluation criteria and ASTCT consensus classification within 30 days after dose infusion (D1-D30), which was considered by the investigator or collaborator to be reasonably related to LCAR-M61S or LCAR-M61D cell therapy.
Time to Cmax (Tmax)
Time Frame: From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years
The time it takes to reach the maximum concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.
Time to the last observed concentration (Tlast)
Time Frame: From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years
The time it takes to reach the last observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.
Incidence, severity, and type of treatment-emergent adverse events (TEAEs)
Time Frame: From the date of signing ICF to the date (2 years after LCAR-M61S and LCAR-M61D cell preparation infusion (Day 1)
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
To determine the recommended dose for phase II clinical trials (RP2D)
Time Frame: Through the last subject of DLT exploration completion, about 2 years
RP2D established through accelerated titration design (ATD) and Bayesian Optimal Interval (BOIN) design
Maximum concentration (Cmax)
Time Frame: From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years
The maximum observed concentration of CAR positive T cells or transgene CAR copy number in peripheral blood.
Area Under the Curve (AUC) of the concentration
Time Frame: From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years
The exposure of CAR positive T cells or transgene CAR copy number in peripheral blood experienced by the subject in a certain time interval.
Secondary Outcomes
- Progression-free survival（PFS）(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)
- Objective Response Rate (ORR)(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)
- Stringent complete response（sCR）(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)
- Minimal residual disease (MRD) negative rate(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression，assessed about 2 years)
- Overall survival（OS）(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)
- Occurrence rate of antidrug antibody(From LCAR-M61S or LCAR-M61D cells preparation infusion until the date of first documented progression or study completion，assessed about 2 years)
- Very Good Partial Response Rate（VGPR）(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)
- Complete response（CR）(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)
- Time-to-response（TTR）(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)
- Duration of response（DOR）(From the 7th days before first dose of pretreatment with chemotherapy until the date of first documented progression or study completion，assessed about 2 years)